Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01)
The summary for the Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01): This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), encourages the submission of grant applications for support of the clinical application of multi-analyte molecular signatures derived from comprehensive molecular annotation of tumors. There is growing recognition in the clinical cancer research community that annotation of tumor specimens with data that integrates information about molecular alterations at the levels of DNA, RNA, and protein provides not only a more complete understanding of tumor biology but also provides a significant opportunity for developing new clinical tools to improve cancer treatment. Translating the knowledge gained from this molecular annotation into tools that can be used in clinical decision-making remains a major challenge. The purpose of this initiative is to build on recent demonstrations that molecular signatures correlate with important clinical parameters in cancer. The goal of this initiative is also to create publications and data sets that will be available and accessible to the scientific community in order to further the development, design, and conduct of future clinical trials (e.g., incorporation of molecular signatures into future clinical trials and large clinical validation studies) and to encourage appropriate commercialization to benefit the public health. The NCI invites investigators to form strategic partnerships that will bring together the multi-disciplinary expertise and resources needed to determine how the information derived from comprehensive molecular analyses can be used to improve patient care and, ultimately, patient outcomes.
|Federal Grant Title:||Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||PAR-11-151|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Cancer Detection and Diagnosis Research|
|Current Application Deadline:||Jun 15, 2012|
|Original Application Deadline:||Jun 15, 2012|
|Posted Date:||Mar 14, 2011|
|Creation Date:||Mar 14, 2011|
|Archive Date:||Jul 16, 2012|
|Total Program Funding:|
|Maximum Federal Grant Award:||$680,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components on applications submitted by U.S. Organizations are allowed.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Rese...
- • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologi...
- • Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)
- • Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic...
- • Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported R...
- • Image-Guided Cancer Interventions (STTR [R41/R42])
- • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
- • In Vivo Cancer Imaging Exploratory/Developmental Grants
- More Grants from the National Institutes of Health
- • BRAIN Initiative: Exploratory Targeted BRAIN Circuits Projects - eTargetedBCP (R21)
- • BRAIN Initiative: Targeted BRAIN Circuits Projects - TargetedBCP (R01)
- • Tools for Clinical Care and Management of Alzheimers Disease (AD) and its Comorbidities (R...
- • Tools for Clinical Care and Management of Alzheimers Disease (AD) and Its Comorbidities (R...
- • Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (...